Nutriband Inc. (NTRBW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nutriband Inc. (NTRBW) trades at $0.3998. Nutriband Inc. is a biotechnology company focused on developing transdermal pharmaceutical products, with a primary focus on abuse-deterrent fentanyl patches. Market cap: $54.6M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for NTRBW: NTRBW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NTRBW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on NTRBW.
How is this calculated? →Nutriband Inc. (NTRBW) Healthcare & Pipeline Overview
Nutriband Inc. is a biotechnology company specializing in transdermal drug delivery systems, with a focus on developing abuse-deterrent opioid patches. Their lead product targets the chronic pain management market, offering a potentially safer alternative to traditional opioid medications, though the company's small size and early stage present challenges.
What Is the Investment Thesis for NTRBW?
Nutriband Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on abuse-deterrent transdermal fentanyl patches addresses a critical need in chronic pain management, potentially capturing a significant market share if approved. The company's small market capitalization of $54.6M reflects its early stage and inherent risks. Key value drivers include successful clinical trials, regulatory approvals, and strategic partnerships. The company's negative P/E ratio of -3.59 and a profit margin of -560.8% highlight its current lack of profitability, making it a speculative investment based on future potential. The high beta of 1.88 indicates high volatility relative to the market.
Based on FMP financials and quantitative analysis
NTRBW Key Highlights
Market capitalization of $54.6M, reflecting its small size and early stage.
- Negative P/E ratio of -3.59, indicating current lack of profitability.
- Profit margin of -560.8%, highlighting significant losses.
- Gross margin of 32.6%, demonstrating potential for profitability if sales increase.
- Beta of 1.88, indicating high volatility compared to the market.
Who Are NTRBW's Competitors?
NTRBW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BOLD Boundless Bio, Inc. | $2.90 | +1.40% | $65.2M | — |
| CVKD Cadrenal Therapeutics, Inc. Common Stock | $1.59 | -3.05% | $5.67M | — |
| IBIO iBio, Inc. | $1.47 | -1.34% | $23.2M | — |
| IGC IGC Pharma, Inc. | $0.28 | -2.84% | $27.8M | — |
| INTS Intensity Therapeutics, Inc. | $4.88 | +16.19% | $13.2M | — |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NTRBW's Key Strengths?
Proprietary transdermal drug delivery technology.
- Focus on abuse-deterrent opioid formulations.
- License agreement for RAMBAM Closed System Transfer Devices.
- Addresses a critical need in chronic pain management.
What Are NTRBW's Weaknesses?
Small size and limited resources.
- Early stage of development with no approved products.
- High dependence on successful clinical trials and regulatory approvals.
- Negative profitability and high operating losses.
What Could Drive NTRBW Stock Higher?
Completion of clinical trials for the abuse-deterrent fentanyl transdermal system.
- FDA review and potential approval of the lead product.
- Development and commercialization of RAMBAM Closed System Transfer Devices.
- Securing strategic partnerships with pharmaceutical companies.
What Are the Key Risks for NTRBW?
Clinical trial failures for the abuse-deterrent fentanyl transdermal system.
- Regulatory delays or rejection of the lead product by the FDA.
- Competition from established pharmaceutical companies with greater resources.
- Dependence on securing additional funding to support operations and product development.
- Product liability lawsuits related to opioid medications.
What Are the Growth Opportunities for NTRBW?
- Expansion of the abuse-deterrent fentanyl patch market: The market for abuse-deterrent opioid formulations is projected to grow as healthcare providers and regulatory agencies seek safer alternatives to traditional opioids. Nutriband's transdermal patch could capture a significant share of this market if it receives regulatory approval and demonstrates clinical efficacy. The timeline for this growth opportunity depends on the successful completion of clinical trials and the subsequent FDA approval process, potentially within the next 3-5 years.
- Development of RAMBAM Closed System Transfer Devices: The license agreement with Rambam Med-Tech Ltd. provides Nutriband with an opportunity to develop and commercialize closed system transfer devices, which are used to safely handle hazardous drugs. This market is driven by the need to protect healthcare workers from exposure to toxic substances. Successful development and commercialization of these devices could generate additional revenue streams for Nutriband, with a potential timeline of 2-4 years.
- Strategic partnerships with pharmaceutical companies: Collaborating with established pharmaceutical companies could provide Nutriband with access to funding, expertise, and distribution channels. These partnerships could accelerate the development and commercialization of its products, increasing its market reach and revenue potential. The timeline for securing these partnerships is uncertain but could materialize within the next 1-3 years.
- Expansion into other therapeutic areas: Nutriband's transdermal drug delivery technology can be applied to a wide range of therapeutic areas beyond pain management. Expanding into areas such as hormone therapy, cardiovascular disease, or central nervous system disorders could significantly increase its market opportunity. This expansion would require additional research and development, with a potential timeline of 3-5 years.
- Geographic expansion into international markets: While Nutriband is currently focused on the US market, expanding into international markets such as Europe and Asia could significantly increase its revenue potential. These markets have a growing demand for advanced drug delivery systems and abuse-deterrent formulations. The timeline for international expansion would depend on regulatory approvals and market entry strategies, potentially within the next 4-6 years.
What Are NTRBW's Competitive Advantages?
- Proprietary transdermal drug delivery technology.
- Patents protecting their abuse-deterrent formulations.
- License agreement for RAMBAM Closed System Transfer Devices.
- Focus on a niche market with high unmet needs.
What Does NTRBW Do?
Nutriband Inc., founded in 2016 and headquartered in Orlando, Florida, is a biotechnology company dedicated to the development of innovative transdermal pharmaceutical products. The company's primary focus is on creating an abuse-deterrent fentanyl transdermal system designed to provide clinicians and patients with a safer, extended-release option for managing chronic pain. This system aims to reduce the potential for opioid abuse, a significant concern in the healthcare industry. In addition to its lead product, Nutriband Inc. holds a license agreement with Rambam Med-Tech Ltd. for the development of RAMBAM Closed System Transfer Devices, further expanding its portfolio of pharmaceutical solutions. The company's strategy centers on leveraging transdermal technology to improve drug delivery and patient outcomes, while addressing critical issues such as opioid abuse. Nutriband is still in the development stage and has a small team of 3 employees.
What Products and Services Does NTRBW Offer?
- Develop abuse-deterrent fentanyl transdermal systems.
- Create extended-release transdermal products for chronic pain management.
- Work to reduce the potential for opioid abuse through innovative drug delivery.
- Develop RAMBAM Closed System Transfer Devices through a license agreement.
- Focus on improving drug delivery and patient outcomes using transdermal technology.
- Address critical issues in healthcare, such as opioid addiction and healthcare worker safety.
How Does NTRBW Make Money?
- Develop and patent transdermal drug delivery technologies.
- License out or partner to commercialize their products.
- Generate revenue through product sales, licensing fees, and royalties.
- Focus on developing abuse-deterrent formulations for opioid medications.
What Industry Does NTRBW Operate In?
Nutriband Inc. operates within the biotechnology industry, specifically targeting the pain management and drug delivery sectors. The market for transdermal drug delivery systems is growing, driven by the demand for non-invasive and controlled-release medication options. The opioid crisis has created a need for abuse-deterrent formulations, positioning Nutriband's lead product to potentially capture a share of this market. Competitors include companies like BOLD, CVKD, IBIO, IGC, and INTS, each with varying approaches to drug delivery and pain management. The industry is characterized by high regulatory hurdles and significant R&D investments.
Who Are NTRBW's Key Customers?
- Patients suffering from chronic pain requiring opioid analgesics.
- Hospitals and clinics managing pain medication for patients.
- Pharmacies dispensing prescription medications.
- Healthcare providers seeking safer opioid alternatives.
Forward Outlook
Wall Street analysts project Nutriband Inc. revenue of about $95.4M for fiscal 2027, with EPS near $1.57.
Financial Health
Nutriband Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 13.14 places it in the safe zone, indicating low near-term bankruptcy risk.
Company Profile
Nutriband Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Orlando, US. The company is led by CEO Gareth Sheridan. NTRBW has traded publicly since 2021.
NTRBW Financials
Bull Case vs Bear Case
Bull Case
- Proprietary transdermal drug delivery technology.
- Focus on abuse-deterrent opioid formulations.
- License agreement for RAMBAM Closed System Transfer Devices.
- Addresses a critical need in chronic pain management.
Bear Case
- Small size and limited resources.
- Early stage of development with no approved products.
- High dependence on successful clinical trials and regulatory approvals.
- Negative profitability and high operating losses.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
NTRBW Latest News
No recent news available for NTRBW.
NTRBW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NTRBW.
Price Targets
Wall Street price target analysis for NTRBW.
NTRBW MoonshotScore
What does this score mean?
The MoonshotScore rates NTRBW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Gareth Sheridan
CEO
Gareth Sheridan is the CEO of Nutriband Inc., a biotechnology company focused on developing transdermal pharmaceutical products. His background includes experience in the pharmaceutical and healthcare industries. He has been instrumental in guiding Nutriband's strategy and product development efforts, particularly in the area of abuse-deterrent opioid formulations. Sheridan's leadership is focused on advancing the company's lead product through clinical trials and securing regulatory approvals. He oversees a small team of 3 employees.
Track Record: Under Gareth Sheridan's leadership, Nutriband Inc. has focused on developing its abuse-deterrent fentanyl transdermal system and securing a license agreement with Rambam Med-Tech Ltd. These efforts represent key milestones in the company's development. The company is still in the early stages, and its future success depends on achieving regulatory approval and commercializing its products.
Nutriband Inc. Healthcare Stock: Key Questions Answered
What does Nutriband Inc. do?
Nutriband Inc. is a biotechnology company that develops transdermal pharmaceutical products, with a primary focus on creating abuse-deterrent opioid formulations. Their lead product is an abuse-deterrent fentanyl transdermal system designed to provide clinicians and patients with a safer, extended-release option for managing chronic pain. The company also has a license agreement to develop RAMBAM Closed System Transfer Devices.
What do analysts say about NTRBW stock?
As of 2026-03-17, there is no readily available analyst coverage for NTRBW due to its small market capitalization and early stage of development. The stock is considered highly speculative, with significant risks and potential rewards. Investors should conduct thorough due diligence and consider their risk tolerance before investing. Key valuation metrics are currently less relevant due to the company's lack of profitability, making it difficult to assess its intrinsic value.
What are the main risks for NTRBW?
The main risks for Nutriband Inc. include clinical trial failures, regulatory delays or rejection, competition from larger pharmaceutical companies, dependence on securing additional funding, and potential product liability lawsuits related to opioid medications. The company's small size and limited resources also pose challenges to its ability to successfully develop and commercialize its products. These risks are inherent in the biotechnology industry, particularly for companies in the early stages of development.
What are the key factors to evaluate for NTRBW?
Evaluate NTRBW on fundamentals, analyst consensus, and risk factors. Nutriband Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does NTRBW data refresh on this page?
NTRBW's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NTRBW's recent stock price performance?
Nutriband Inc. (NTRBW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary transdermal drug delivery technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NTRBW overvalued or undervalued right now?
Nutriband Inc. (NTRBW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NTRBW before investing?
Before investing in Nutriband Inc. (NTRBW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- The company is in an early stage of development, and its future success is uncertain.